[Hepatotoxicity of chemotherapy]

Area of Science:

• Oncology
• Hepatology
• Pharmacology

Background:

• Chemotherapy necessitates pre-treatment liver function assessment to guide drug selection and dosage.
• Hepatotoxicity from medications and alcohol, coupled with immunocompromise, increases susceptibility to liver infections like viral hepatitis.
• Hepatitis B reactivation is a concern during chemotherapy.

Purpose of the Study:

• To highlight the importance of liver function assessment in chemotherapy patients.
• To discuss the management of hepatic complications during cancer treatment.
• To emphasize the role of clinical judgment in preventing and treating chemotherapy-related liver issues.

Main Methods:

• Review of existing literature on chemotherapy-induced hepatotoxicity.
• Analysis of the impact of high-dose chemotherapy regimens on liver function.
• Discussion of pharmacological interventions, such as lamivudine for hepatitis B reactivation.

Main Results:

• Pre-treatment liver function tests are crucial for identifying drugs requiring dose modification or avoidance.
• High-dose chemotherapy regimens are associated with increased drug toxicities.
• Lamivudine demonstrates efficacy in managing hepatitis B reactivation during chemotherapy.
• Clinical vigilance is essential for identifying and managing hepatic manifestations.

Conclusions:

• Careful liver function assessment is vital before initiating chemotherapy.
• Management of chemotherapy-induced liver complications requires a high index of suspicion and clinical judgment.
• Proactive monitoring and intervention are necessary to mitigate risks associated with cancer treatment.